Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Farmeconomia. Health economics and therapeutic pathways
427 Publications
collected from a compatible aggregator


  • A cost-effectiveness analysis of E/C/F/TAF vs three boosted regimens in the Italian context

    Pradelli, Lorenzo; Di Perri, Giovanni; Rizzardini, Giuliano; Martelli, Elisa; Giardina, Stefano; Povero, Massimiliano (2017)
    BACKGROUND: Highly Active Antiretroviral Therapy (HAART) has transformed HIV into a lifelong condition. Following the chronicity of the disease, and significant increase in lifespan – the prevalence of comorbidities increased in HIV+ subjects that are exposed both to a higher risk of developing cardiovascular disease, renal disease, osteopenia/osteoporosis and diabetes, and to the risk of developing them early. Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate (E/C/F/TAF), ...

    Albutrepenonacog alfa (Idelvion®) for the treatment of Italian patients with hemophilia B: a budget impact model

    Pradelli, Lorenzo; Villa, Sara; Castaman, Giancarlo (2018)
    BACKGROUND: Enhanced pharmacokinetic profile of albutrepenonacog alfa allows to prolong the interdose period in prophylaxis, maintaining higher trough level, and to reduce dosage needed for bleeding. This improvement could lead to a better efficiency of the hemophilia B treatment.OBJECTIVES: To estimate the impact of this new drug on the Italian National Health System (NHS).METHODS: A model was developed from the NHS perspective to assess the budget impact of treating severe hemophilia B with...

    Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation

    Celeste, Maria Grazia; De Marco, Francesca; Fresco, Claudio; Musumeci, Giuseppe; Ravasio, Roberto (2017)
    BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20) are indicated for the prevention of thromboembolic events in patients with Non-Valvular Atrial Fibrillation (NVAF). Outcomes from observational study demonstrated that D150 and R20 reduced the rate of thromboembolic events.OBJECTIVE: This analysis estimated the budget impact of the use of D150 and R20 for the treatment of NAFV patients in Italy.METHODS: A budget-impact model (BIM) was developed to estimate the direct costs u...

    [Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis]

    Mantovani, Lorenzo Giovanni; Furneri, Gianluca; Cortesi, Paolo Angelo; Amato, Maria Pia; Caputi, Achille Patrizio; Piacentini, Patrizio; Solari, Alessandra; Pozzilli, Carlo; Comi, Giancarlo (2017)
    The present health technology assessment (HTA) evaluates the clinical and economic profile of delayed-release dimethylfumarate (DMF, also known as gastro-resistant DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in Italy. Chapter 1 briefly introduces the condition (multiple sclerosis and, more specifically, the relapsing-remitting form) and provides an overall description of the main therapeutic options for physicians, in terms of clinical evidence, regulatory status in...

    Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre

    Variola, Angela; Massella, Arianna; Geccherle, Andrea; Bocus, Paolo; Tessari, Roberto; Zuppini, Teresa; Ravasio, Roberto (2017)
    BACKGROUND: Inflammatory bowel disease (IBD) represents a group of chronic conditions characterized by elevated costs. Over the last years, also a considerable healthcare burden associated with IBD has emerged, due to an increasing use of biological drugs and hospitalization costs. Despite the creation of local or regional databases, data regarding healthcare expenditure are lacking in Italy.AIM: To evaluate the treatment cost (biological drugs and hospitalizations) for patients with ulcerati...
  • No data provider research data found
  • Latest Documents Timeline

    Chart is loading... It may take a bit of time. Please be patient and don't reload the page.

    Document Types

    Chart is loading... It may take a bit of time. Please be patient and don't reload the page.

Share - Bookmark